Reaction
Neuromyelitis Optica Spectrum Disorder reporting signals
As of the last recalculation, Neuromyelitis Optica Spectrum Disorder appears in 1,287 FAERS reports alongside 8 co-occurring drug terms. The strongest observed disproportionality signal is RAVULIZUMAB (PRR 92.6).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Ravulizumab | 73 | 92.6 | 93.1 |
| Eculizumab | 124 | 40.7 | 40.8 |
| Rituximab | 304 | 30.1 | 30.2 |
| Diphenhydramine Hydrochloride Capsule, Liquid Filled | 30 | 23.2 | 23.3 |
| Azathioprine | 80 | 15.6 | 15.6 |
| Mycophenolate Mofetil | 96 | 12.3 | 12.3 |
| Mycophenolate Mofetil Hydrochloride | 96 | 12.3 | 12.3 |
| Fingolimod Hcl | 35 | 6.7 | 6.7 |